Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Luis Barreto
CanSino Biologics Inc.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
65
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double blinded phase 3 trial
Number of pages: 34
Posted: 01 Oct 2025
Adora Rooyakkers
,
Lingyun Ye
,
Pedro E. Cahn
,
Guillermo M. Ruiz-Palacios
,
Aamer Ikram
,
Fernando Lanas
,
Sergio Munoz
,
Omar Sued
,
Dmitry Lioznov
,
Vitalina Dzutseva
,
Ghazala Parveen
,
Tatyana Zubkova
,
Jing-Xin Li
,
Joanne Marie Langley
,
Ruijie Wang
, Luis Barreto,
Jin-Bo Gou
,
Tao Zhu
,
Carrie A. Whittle
and
Scott A. Halperin
affiliation not provided to SSRN
, Dalhousie University, Fundación Huésped,
affiliation not provided to SSRN
, National Institutes of Health, Chak Shahzad, Universidad de la Frontera, Independent,
affiliation not provided to SSRN
, Ministry of Health of the Russian Federation, Novosibirsk State University,
affiliation not provided to SSRN
, Ministry of Health of the Russian Federation, Nanjing Medical University, Dalhousie University, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Dalhousie University and Dalhousie University
Downloads
65
(924,743)
View PDF
Download
Abstract:
Efficacy, safety, immunogenicity, adenovirus type 5, vaccine, SARS-CoV-2, phase 3, booster
Feedback
